
Currently out of the existing stock ratings of Matt Larew, 1 are a HOLD (100%).
Analyst Matt Larew, currently employed at WILLIAM BLAIR,
Matt Larew has documented 2 price targets and ratings displayed on 9 stocks.
Most recent stock forecast was given on AMED, at 30-Dec-2024.
Analyst best performing recommendations are on DNA (GINKGO BIOWORKS HOLDINGS).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Sell Since 26-Jun-2024
$5
$-2.46 (-32.98%)
$5
2 months 17 days ago
(04-Sep-2026)
4/9 (44.44%)
$-1.95 (-28.06%)
50
Buy Since 20-Sep-2024
$9
$1.54 (20.64%)
$12
3 months 14 days ago
(07-Aug-2026)
3/3 (100%)
$1.03 (12.92%)
129
Buy Since 01-Mar-2022
$3
$120
2 years 2 months 4 days ago
(17-Sep-2024)
0/5 (0%)
$-3.81 (-55.95%)
Sell Since 20-Aug-2024
$7
2 years 3 months 1 days ago
(20-Aug-2024)
1/1 (100%)
$-0.71 (-9.21%)
10
Hold Since 04-Oct-2022
$40
$40
2 years 3 months 1 days ago
(20-Aug-2024)
0/4 (0%)
$32.29 (418.81%)
What Year was the first public recommendation made by Matt Larew?